Eisai postpones NerBloc launch

NerBloc, a botulinum toxin type B neuromuscular-blocking agent, has been approved by the Japanese regulatory authority in 21 January 2011.

NerBloc has showed improvement in TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale) total score from baseline to week four compared with placebo in a double-blind placebo-controlled trial (Study 131).

Eisai said that as it cannot ensure a stable supply of NerBloc due to manufacturing capacity-related issues that have arisen at the fill finish site contracted by the supplier it has taken the decision to delay the launch and price registration of the product.